DrugsNews.net

Drugs Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Mediexplorer.it

Search results for "Rituximab"

The NICE ( National Institute for Health and Clinical Excellence ) has published final guidance on the use of Rituximab ( Mabthera; US: Rituxan ) for the treatment of rheumatoid arthritis and Adalimum ...


Bayer Schering Pharma AG and Genzyme Europe BV have informed Healthcare Professionals on six infection-related deaths, reported from a trial ( CALGB10101 ) in which previously untreated, symptomatic ...


Genzyme Europe BV has informed Healthcare Professional of six infection-related deaths, reported from a trial ( CALGB10101 ) in which previously untreated, symptomatic B-cell chronic lymphocytic leuke ...


Rituximab ( MabThera; US: Rituxan ) is a monoclonal antibody representing a glycosylated immunoglobulin indicated for the treatment of: - Non-Hodgkin’s lymphoma: in combination with chemotherapy fo ...


Bayer HealthCare and Genzyme, in collaboration with Health Canada, informed of important safety information regarding the use of MabCampath ( Alemtuzumab ) as consolidation therapy following combinati ...


In the 2008, the FDA ( Food and Drug Administration ) has approved Bendamustine hydrochloride ( Treanda ), an intravenously administered alkylating agent, for the treatment of patients with indolent B ...


Rituximab ( MabThera; US: Rituxan ) is a monoclonal antibody representing a glycosylated immunoglobulin indicated for the treatment of: - Non-Hodgkin’s lymphoma: in combination with ...


Roche has announced new Phase II efficacy data from the investigational compound GA101 ( RG 1759; Obinutuzumab ) in relapsed / refractory non-Hodgkin's lymphoma ( NHL ).GA101 is the first type II ...


The European Commission has granted marketing authorization for Zydelig ( Idelalisib ), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers, chronic lymphocytic leukemia ( ...


The European Commission ( EU ) has approved a variation to the terms of the marketing authorisation of Velcade ( Bortezomib ) in combination with Rituximab, Cyclophosphamide, Doxorubicin and Prednison ...


The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer drugs fund list. The decision summaries record how each drug/drug indica ...


The Committee for Medicinal Products for Human Use ( CHMP ) of European Medicine Agency ( EMA ) has adopted a positive opinion for Gazyvaro ( Obinutuzumab; Gazyva in U.S. ) in combination with Bendam ...


The FDA ( Food and Drug Administration ) has granted accelerated approval to Polatuzumab vedotin-piiq ( Polivy; Polatuzumab vedotin ), a CD79b-directed antibody-drug conjugate indicated in combination ...


Tthe US Food and Drug Administration ( FDA ) has approved Calquence ( Acalabrutinib ) for adult patients with chronic lymphocytic leukaemia ( CLL ) or small lymphocytic lymphoma ( SLL ). The US appr ...


The European Commission has granted conditional marketing authorisation for Polivy ( Polatuzumab vedotin ), in combination with Bendamustine plus MabThera ( Rituximab ) ( BR ), for the treatment of ad ...